GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $4.2273.

GDRX has been the topic of a number of analyst reports. UBS Group upped their price objective on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wells Fargo & Company increased their price target on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Barclays lifted their price objective on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Thursday, August 20th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Finally, TD Cowen raised their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th.

Insider Activity at GoodRx

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 2,760,995 shares of company stock worth $9,673,207. Insiders own 5.87% of the company’s stock.

Hedge Funds Weigh In On GoodRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. Prescott Group Capital Management L.L.C. acquired a new stake in GoodRx during the 4th quarter worth approximately $4,812,000. Technology Crossover Management X Ltd. bought a new position in GoodRx during the 2nd quarter worth $4,762,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of GoodRx by 10,242.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock worth $4,072,000 after buying an additional 1,488,137 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of GoodRx by 192.6% during the second quarter. California State Teachers Retirement System now owns 1,684,431 shares of the company’s stock worth $4,851,000 after buying an additional 1,108,766 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of GoodRx by 188.0% in the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock valued at $3,140,000 after acquiring an additional 756,209 shares during the period. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Performance

Shares of GDRX stock opened at $3.39 on Tuesday. The stock has a market cap of $1.16 billion, a PE ratio of 84.77, a price-to-earnings-growth ratio of 1.69 and a beta of 1.59. GoodRx has a one year low of $1.77 and a one year high of $5.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a 50-day moving average of $3.33 and a 200-day moving average of $2.75.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same quarter in the prior year, the firm earned $0.09 earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts expect that GoodRx will post 0.16 earnings per share for the current year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a consumer-focused healthcare technology platform in the United States. Its website and mobile application help consumers compare prescription drug prices at participating pharmacies and access coupons and other savings tools. GoodRx also provides information about medications, health conditions and treatment options.

The company offers GoodRx Gold, a subscription-based program that provides additional prescription savings, as well as telehealth services that connect consumers with licensed healthcare professionals for certain medical consultations and prescriptions.